NDA Submitted (38 companies)
Companies with at least one active program at NDA Submitted.
| Ticker | Company | Therapeutic areas | NDA Submitted programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACHV | Achieve Life Sciences | — | 1 | NDA Submitted | $692M | 2 |
| AGIO | Agios Pharmaceuticals | HematologyMetabolic Rare | 1 | Approved | $1.76B | 7 |
| ALDX | Aldeyra Therapeutics | DermatologyOncology+1 | 1 | NDA Submitted | $38.3M | 5 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 1 | Approved | $1.39B | 9 |
| AXSM | Axsome Therapeutics | Neurology Rare | 1 | Approved | $6.96B | 15 |
| BLTE | Belite Bio | MetabolicOphthalmology Rare | 1 | NDA Submitted | $6.21B | 6 |
| CAPR | Capricor Therapeutics | Infectious DiseaseNeurology Rare | 1 | NDA Submitted | $523M | 2 |
| CGON | CG Oncology | Oncology | 1 | NDA Submitted | $6.79B | 1 |
| CING | Cingulate | Neurology | 1 | NDA Submitted | $61.9M | 1 |
| CLNN | Clene | Neurology Rare | 1 | NDA Submitted | $56.9M | 5 |
| COGT | Cogent Biosciences | HematologyOncology Rare | 3 | NDA Submitted | $5.51B | 7 |
| CMPS | COMPASS Pathways | Neurology | 1 | NDA Submitted | $1.22B | 3 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 1 | NDA Submitted | $728M | 10 |
| DBVT | DBV Technologies | Immunology | 1 | NDA Submitted | $3.29B | 2 |
| DYN | Dyne Therapeutics | MetabolicNeurology Rare | 1 | NDA Submitted | $3.39B | 10 |
| ETON | Eton Pharmaceuticals | GI/HepatologyInfectious Disease+3 Rare | 1 | Approved | $1.63B | 17 |
| EXEL | Exelixis | CardiovascularOncology | 1 | Approved | $17.0B | 23 |
| GOSS | Gossamer Bio | Cardiovascular Rare | 1 | NDA Submitted | — | 4 |
| GRCE | Grace Therapeutics | Neurology | 1 | NDA Submitted | $38.9M | 1 |
| IDYA | IDEAYA Biosciences | Oncology | 1 | NDA Submitted | $3.02B | 14 |
| IMNM | Immunome | Oncology Rare | 1 | NDA Submitted | $2.13B | 9 |
| INBX | Inhibrx Biosciences | Oncology | 1 | NDA Submitted | $1.24B | 6 |
| NTLA | Intellia Therapeutics | CardiovascularImmunology Rare | 1 | NDA Submitted | $1.59B | 3 |
| KYTX | Kyverna Therapeutics | ImmunologyNeurology+1 Rare | 1 | NDA Submitted | $302M | 7 |
| LRMR | Larimar Therapeutics | Neurology Rare | 1 | NDA Submitted | $248M | 1 |
| MLYS | Mineralys Therapeutics | CardiovascularRenal+1 | 1 | NDA Submitted | $1.36B | 3 |
| MLTX | MoonLake Immunotherapeutics | DermatologyImmunology Rare | 1 | NDA Submitted | $981M | 4 |
| NAMS | NewAmsterdam Pharma | CardiovascularMetabolic+1 | 3 | NDA Submitted | $2.27B | 6 |
| NRXP | NRX Pharmaceuticals | Neurology Rare | 2 | Approved | $103M | 7 |
| PYPD | PolyPid | Infectious DiseaseOncology | 1 | NDA Submitted | $125M | 3 |
| RVMD | Revolution Medicines | Oncology | 1 | Approved | $41.6B | 11 |
| SMMT | Summit Therapeutics | Oncology | 1 | NDA Submitted | $13.1B | 6 |
| UNCY | Unicycive Therapeutics | Renal | 1 | NDA Submitted | $98.9M | 2 |
| QURE | uniQure | HematologyMetabolic+1 Rare | 1 | Approved | $1.52B | 4 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 4 | Approved | $231M | 27 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.68B | 28 |
| XENE | Xenon Pharmaceuticals | Neurology Rare | 1 | NDA Submitted | $3.79B | 9 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | 1 | NDA Submitted | $1.92B | 11 |
No companies match.